Designs for clinical trials to test the efcacy of therapeutics in progressive multifocal leukoencephalopathy

598.O’Brien P, Fleming T (1979). A multiple testing procedure for clinical trials. Biometrics 35: 549–556.Silver SA, Arthur RR, Erozan YS, Sherman ME, McArthur JC, Uematsu S (1995). Diagnosis of progressive multi-focal leukoencephalopathy by stereotactic brain biopsy utilizing immunohistochemistry and the polymerasechain reaction. Acta Cytol 39: 35–44. Sindic C, TrebstC, VanAntwerpenM, Frye S, EnzensbergerW, Hunsmann G, Luke W, Weber T (1997). Detection of CSF-speciŽc oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocalleukoencephalopathy. J Neuroimmunol 76: 100–104. TaouŽk Y, Gasnault J, Karaterki A, Pierre Ferey M,Marchadier E, Goujard C, Lannuzel A, Delfraissy JF, Dussaix E (1998). Prognostic value of JC virus load incerebrospinal uid of patients with progressivemultifocal leukoencephalopathy. J Infect Dis 178: 1816–1820.Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boue F, Billaud E, Costagliola D (1999). Survival improve-ment of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. ClinicalEpidemiology Group. French Hospital Database on HIV. AIDS 13: 1881–1887.Weber T, Trebst C, Frye S, Cinque P, Vago L, Sindic C, Schulz-Schaeffer W, Kretzschmar H, Enzensberger W,Hunsmann G, Luke W (1997). Analysis of the systemic and intrathecal humoral immune response in progres-sive multifocal leukoencephalopathy. J Infect Dis 176: 250–254.Weiner SM, Laubenberger J, Muller K, Schneider J, Kreisel W (2000). Fatal course of HIV-associated progres-sive multifocal leukoencephalopathy despite successful highly active antiretroviral therapy. J Infect 40: 100–102. Yiannoutsos C, Major E, Curfman B, Jensen P, GravellM, Hou J, Clifford D, Hall C (1999). Relation of JC virus DNa in the CSF to survival in AIDS patientswith biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 45: 816–820.